EO Care is a digital health platform that provides guidance for cannabinoid-based treatments. The company has developed a model for group plan sponsors to estimate the theoretical healthcare cost impacts of using evidence-based, clinically guided cannabinoids to mitigate symptoms of cancer, chronic pain, sleep disorders and insomnia, and anxiety. EO Care recently commissioned Milliman to review its model methodology to determine its appropriateness. This report:

• Describes EO Care’s approach to determining the model’s input values
• Outlines EO Care’s approach for estimating theoretical healthcare cost impacts for group plan sponsors
• Discusses potential limitations of the methodology 
• Outlines important caveats and limitations 

This report was commissioned by EO Care.